Effect of alendronate on bone mineral density and bone turnover markers in post-gastrectomy osteoporotic patients

Jun Iwamoto, Mitsuyoshi Uzawa, Yoshihiro Sato, Tsuyoshi Takeda, Hideo Matsumoto

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Alendronate decreases the urinary levels of cross-linked N-terminal telopeptides of type I collagen (NTX; about 45% at 3 months) and serum levels of alkaline phosphatase (ALP; about 27% at 24 months), leading to an increase in lumbar spine bone mineral density (BMD; about 9% at 24 months) in postmenopausal Japanese women with osteoporosis. However, the effectiveness of oral bisphosphonates on osteoporosis remains to be established in patients who have undergone a gastrectomy. The objective of the present case series study was to examine the effect of alendronate on BMD and bone turnover markers in post-gastrectomy osteoporotic patients. Sixteen patients (3 men and 13 postmenopausal women) with osteoporosis, who had undergone a gastrectomy (mean age: 69.1 years), were recruited in our outpatient clinic. All the patients were treated with alendronate (5 mg daily or 35 mg weekly) for 24 months. The effects of alendronate on lumbar spine (women) or total hip (men) BMD and urinary NTX and serum ALP levels were examined. A total or partial gastrectomy had been performed for eight patients each. The mean duration after surgery was 16.0 years. With alendronate therapy, urinary NTX levels significantly decreased at 3 months (-27.0%). Serum ALP levels decreased (-12.1%) and lumbar spine BMD increased (+5.2%), but total hip BMD did not significantly change (+0.6%) at 24 months. No severe adverse events were observed, and alendronate therapy was well tolerated. These results suggest that alendronate mildly increases lumbar spine BMD by mildly reducing bone turnover in osteoporotic patients after a gastrectomy.

Original languageEnglish
Pages (from-to)202-208
Number of pages7
JournalJournal of Bone and Mineral Metabolism
Volume28
Issue number2
DOIs
Publication statusPublished - 2010 Mar

Fingerprint

Alendronate
Bone Remodeling
Gastrectomy
Bone Density
Bone and Bones
Spine
Osteoporosis
Hip
Serum
Diphosphonates
Ambulatory Care Facilities
Alkaline Phosphatase
Therapeutics

Keywords

  • Alendronate
  • Bone mineral density (BMD)
  • Bone turnover
  • Gastrectomy
  • Osteoporosis

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine

Cite this

Effect of alendronate on bone mineral density and bone turnover markers in post-gastrectomy osteoporotic patients. / Iwamoto, Jun; Uzawa, Mitsuyoshi; Sato, Yoshihiro; Takeda, Tsuyoshi; Matsumoto, Hideo.

In: Journal of Bone and Mineral Metabolism, Vol. 28, No. 2, 03.2010, p. 202-208.

Research output: Contribution to journalArticle

Iwamoto, Jun ; Uzawa, Mitsuyoshi ; Sato, Yoshihiro ; Takeda, Tsuyoshi ; Matsumoto, Hideo. / Effect of alendronate on bone mineral density and bone turnover markers in post-gastrectomy osteoporotic patients. In: Journal of Bone and Mineral Metabolism. 2010 ; Vol. 28, No. 2. pp. 202-208.
@article{4402431080334136a85910ca36d00fd9,
title = "Effect of alendronate on bone mineral density and bone turnover markers in post-gastrectomy osteoporotic patients",
abstract = "Alendronate decreases the urinary levels of cross-linked N-terminal telopeptides of type I collagen (NTX; about 45{\%} at 3 months) and serum levels of alkaline phosphatase (ALP; about 27{\%} at 24 months), leading to an increase in lumbar spine bone mineral density (BMD; about 9{\%} at 24 months) in postmenopausal Japanese women with osteoporosis. However, the effectiveness of oral bisphosphonates on osteoporosis remains to be established in patients who have undergone a gastrectomy. The objective of the present case series study was to examine the effect of alendronate on BMD and bone turnover markers in post-gastrectomy osteoporotic patients. Sixteen patients (3 men and 13 postmenopausal women) with osteoporosis, who had undergone a gastrectomy (mean age: 69.1 years), were recruited in our outpatient clinic. All the patients were treated with alendronate (5 mg daily or 35 mg weekly) for 24 months. The effects of alendronate on lumbar spine (women) or total hip (men) BMD and urinary NTX and serum ALP levels were examined. A total or partial gastrectomy had been performed for eight patients each. The mean duration after surgery was 16.0 years. With alendronate therapy, urinary NTX levels significantly decreased at 3 months (-27.0{\%}). Serum ALP levels decreased (-12.1{\%}) and lumbar spine BMD increased (+5.2{\%}), but total hip BMD did not significantly change (+0.6{\%}) at 24 months. No severe adverse events were observed, and alendronate therapy was well tolerated. These results suggest that alendronate mildly increases lumbar spine BMD by mildly reducing bone turnover in osteoporotic patients after a gastrectomy.",
keywords = "Alendronate, Bone mineral density (BMD), Bone turnover, Gastrectomy, Osteoporosis",
author = "Jun Iwamoto and Mitsuyoshi Uzawa and Yoshihiro Sato and Tsuyoshi Takeda and Hideo Matsumoto",
year = "2010",
month = "3",
doi = "10.1007/s00774-009-0116-0",
language = "English",
volume = "28",
pages = "202--208",
journal = "Journal of Bone and Mineral Metabolism",
issn = "0914-8779",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Effect of alendronate on bone mineral density and bone turnover markers in post-gastrectomy osteoporotic patients

AU - Iwamoto, Jun

AU - Uzawa, Mitsuyoshi

AU - Sato, Yoshihiro

AU - Takeda, Tsuyoshi

AU - Matsumoto, Hideo

PY - 2010/3

Y1 - 2010/3

N2 - Alendronate decreases the urinary levels of cross-linked N-terminal telopeptides of type I collagen (NTX; about 45% at 3 months) and serum levels of alkaline phosphatase (ALP; about 27% at 24 months), leading to an increase in lumbar spine bone mineral density (BMD; about 9% at 24 months) in postmenopausal Japanese women with osteoporosis. However, the effectiveness of oral bisphosphonates on osteoporosis remains to be established in patients who have undergone a gastrectomy. The objective of the present case series study was to examine the effect of alendronate on BMD and bone turnover markers in post-gastrectomy osteoporotic patients. Sixteen patients (3 men and 13 postmenopausal women) with osteoporosis, who had undergone a gastrectomy (mean age: 69.1 years), were recruited in our outpatient clinic. All the patients were treated with alendronate (5 mg daily or 35 mg weekly) for 24 months. The effects of alendronate on lumbar spine (women) or total hip (men) BMD and urinary NTX and serum ALP levels were examined. A total or partial gastrectomy had been performed for eight patients each. The mean duration after surgery was 16.0 years. With alendronate therapy, urinary NTX levels significantly decreased at 3 months (-27.0%). Serum ALP levels decreased (-12.1%) and lumbar spine BMD increased (+5.2%), but total hip BMD did not significantly change (+0.6%) at 24 months. No severe adverse events were observed, and alendronate therapy was well tolerated. These results suggest that alendronate mildly increases lumbar spine BMD by mildly reducing bone turnover in osteoporotic patients after a gastrectomy.

AB - Alendronate decreases the urinary levels of cross-linked N-terminal telopeptides of type I collagen (NTX; about 45% at 3 months) and serum levels of alkaline phosphatase (ALP; about 27% at 24 months), leading to an increase in lumbar spine bone mineral density (BMD; about 9% at 24 months) in postmenopausal Japanese women with osteoporosis. However, the effectiveness of oral bisphosphonates on osteoporosis remains to be established in patients who have undergone a gastrectomy. The objective of the present case series study was to examine the effect of alendronate on BMD and bone turnover markers in post-gastrectomy osteoporotic patients. Sixteen patients (3 men and 13 postmenopausal women) with osteoporosis, who had undergone a gastrectomy (mean age: 69.1 years), were recruited in our outpatient clinic. All the patients were treated with alendronate (5 mg daily or 35 mg weekly) for 24 months. The effects of alendronate on lumbar spine (women) or total hip (men) BMD and urinary NTX and serum ALP levels were examined. A total or partial gastrectomy had been performed for eight patients each. The mean duration after surgery was 16.0 years. With alendronate therapy, urinary NTX levels significantly decreased at 3 months (-27.0%). Serum ALP levels decreased (-12.1%) and lumbar spine BMD increased (+5.2%), but total hip BMD did not significantly change (+0.6%) at 24 months. No severe adverse events were observed, and alendronate therapy was well tolerated. These results suggest that alendronate mildly increases lumbar spine BMD by mildly reducing bone turnover in osteoporotic patients after a gastrectomy.

KW - Alendronate

KW - Bone mineral density (BMD)

KW - Bone turnover

KW - Gastrectomy

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=77952498232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952498232&partnerID=8YFLogxK

U2 - 10.1007/s00774-009-0116-0

DO - 10.1007/s00774-009-0116-0

M3 - Article

VL - 28

SP - 202

EP - 208

JO - Journal of Bone and Mineral Metabolism

JF - Journal of Bone and Mineral Metabolism

SN - 0914-8779

IS - 2

ER -